HLA-DQB1 REFLECTS AN ANTIGEN-PRESENTATION-ASSOCIATED IMMUNE MICROENVIRONMENT IN BLADDER CANCER AND SHOWS RESPONSE-RELATED SIGNALS IN AN ATEZOLIZUMAB-TREATED COHORT

Authors

  • FangMing Xu † The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, Guangxi, China.
  • ZhongYi Qin † The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, Guangxi, China. Guilin Medical University, Guilin 541199, Guangxi, China.
  • JiaQiang Pan (Corresponding Author) The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, Guangxi, China.

† These authors contributed equally to this work.

Keywords:

Bladder cancer, HLA-DQB1, Antigen presentation, Immune microenvironment, TCGA, GSE13507, IMvigor210, Immunotherapy

Abstract

Bladder cancer is a heterogeneous malignancy with variable immune infiltration and limited response rates to immune checkpoint blockade. HLA-DQB1, a major histocompatibility complex class II gene involved in antigen presentation, may participate in tumor immune regulation. However, its expression pattern, prognostic relevance, immune microenvironmental associations, and immunotherapy-related significance in bladder cancer remain incompletely characterized. Transcriptomic and clinical data of bladder cancer were obtained from TCGA-BLCA. HLA-DQB1 expression was compared between tumor and normal tissues, and its association with overall survival was evaluated using Kaplan–Meier and Cox regression analyses. Single-sample gene set enrichment analysis was used to estimate immune-cell infiltration. Correlations between HLA-DQB1 and immune checkpoints, antigen-presentation genes, and immune-related modules were assessed using Spearman correlation analysis. Differential expression analysis between HLA-DQB1-high and HLA-DQB1-low tumors was performed using limma, followed by GO and Hallmark GSEA. External validation was conducted using GSE13507. Immunotherapy-related analyses were further performed in the IMvigor210 atezolizumab-treated urothelial carcinoma cohort. Public single-cell visualization was used as exploratory evidence of HLA-DQB1 cellular heterogeneity. In TCGA-BLCA, HLA-DQB1 expression did not differ significantly between tumor and normal tissues and was not significantly associated with overall survival. However, HLA-DQB1 showed strong positive associations with multiple immune-cell infiltration scores, including CD8 T cells, Tfh cells, macrophages, Th1 cells, NK cells, T cells, and Treg cells. HLA-DQB1 was also strongly correlated with antigen-presentation genes and immune-related markers, including HLA-DRA, HLA-DPA1, CD74, CIITA, PDCD1, CTLA4, HAVCR2, CXCL9, and CXCL10. GSEA revealed enrichment of immune activation, antigen presentation, interferon response, and inflammatory pathways in the HLA-DQB1-high group. In GSE13507, although tumor tissues showed lower HLA-DQB1 expression than normal bladder mucosa, the immune associations of HLA-DQB1 were externally reproduced. HLA-DQB1 was significantly correlated with antigen-presentation, myeloid/APC, T-cell-inflamed, and checkpoint-exhaustion module scores in both TCGA-BLCA and GSE13507. In the IMvigor210 cohort, HLA-DQB1 expression tended to be higher in responders, and after adjustment for tumor mutational burden, higher HLA-DQB1 expression was significantly associated with increased odds of response to atezolizumab. HLA-DQB1 expression showed cohort-dependent tumor-versus-normal patterns and was not significantly associated with overall survival in TCGA-BLCA. Across independent transcriptomic cohorts, HLA-DQB1 was consistently associated with MHC-II antigen-presentation-related and immune-inflamed transcriptional programs. Exploratory analysis of an atezolizumab-treated urothelial carcinoma cohort suggested an association with treatment response after adjustment for tumor mutational burden, although this finding requires further validation. Overall, HLA-DQB1 appears to reflect a broader immune-related transcriptional state rather than a validated independent prognostic or immunotherapy response biomarker.

References

[1] Guo C C, Lee S, Lee J G, et al. Molecular profile of bladder cancer progression to clinically aggressive subtypes. Nat Rev Urol, 2024, 21: 391-405. DOI: 10.1038/s41585-023-00847-7.

[2] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clinicians, 2024, 74: 229-263. DOI: 10.3322/caac.21834.

[3] Dyrskjøt L, Hansel D E, Efstathiou J A, et al. Bladder cancer. Nat Rev Dis Primers, 2023, 9: 58. DOI: 10.1038/s41572-023-00468-9.

[4] Bellmunt J, De Wit R, Vaughn D J, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med, 2017, 376: 1015-1026. DOI: 10.1056/NEJMoa1613683.

[5] Rosenberg J E, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. The Lancet, 2016, 387: 1909-1920. DOI: 10.1016/S0140-6736(16)00561-4.

[6] Huang P, Wang J, Yu Z, et al. Redefining bladder cancer treatment: innovations in overcoming drug resistance and immune evasion. Front Immunol, 2025, 16: 1537808. DOI: 10.3389/fimmu.2025.1537808.

[7] Li J, Lin P, Wang H, et al. Pan-cancer analysis of spatial transcriptomics reveals heterogeneous tumor spatial microenvironment. Cell Reports Medicine, 2026, 7: 102751. DOI: 10.1016/j.xcrm.2026.102751.

[8] Lai L, Ran S, Li Y, et al. Cytotoxic CD4+ T cells: origin, biological functions, diseases and therapeutic targets. Sig Transduct Target Ther, 2026, 11: 85. DOI: 10.1038/s41392-025-02533-z.

[9] Lau D, Elliott T. Imaging antigen processing and presentation in cancer. Immunotherapy Advances, 2024, 5: ltaf002. DOI: 10.1093/immadv/ltaf002.

[10] Ishina I A, Zakharova M Y, Kurbatskaia I N, et al. MHC Class II Presentation in Autoimmunity. Cells, 2023, 12: 314. DOI: 10.3390/cells12020314.

[11] Liu D H, Mou F F, An M, et al. Human leukocyte antigen and tumor immunotherapy (Review). Int J Oncol, 2023, 62: 68. DOI: 10.3892/ijo.2023.5516.

[12] Zhou M, Pan S, Zhang Y, et al. Biological mechanism and immune response of MHC-II expression in tumor cells. Cancer Biol Med, 2025: 1-23. DOI: 10.20892/j.issn.2095-3941.2025.0248.

[13] Liu J, Song X, Guo W, et al. Unlock the Code of MHC II-enabled Cancer Immunotherapy. 2025. DOI: 10.22541/au.173782765.53711494/v1.

[14] Damian D. Human Leukocyte Antigen (HLA) and Tumor Immunity: A Critical Link in Cancer Immunotherapy. Immunity Inflam & Disease, 2026, 14: e70363. DOI: 10.1002/iid3.70363.

[15] Yamaguchi H, Hsu J M, Sun L, et al. Advances and prospects of biomarkers for immune checkpoint inhibitors. Cell Reports Medicine, 2024, 5: 101621. DOI: 10.1016/j.xcrm.2024.101621.

[16] Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade. Journal of Clinical Investigation, 2017, 127: 2930-2940. DOI: 10.1172/JCI91190.

[17] Yang K, Halima A, Chan T A. Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy. Nat Rev Clin Oncol, 2023, 20: 604-623. DOI: 10.1038/s41571-023-00789-4.

[18] Fridman W H, Meylan M, Petitprez F, et al. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol, 2022, 19: 441-457. DOI: 10.1038/s41571-022-00619-z.

Downloads

Published

2026-11-13

How to Cite

FangMing Xu, ZhongYi Qin, JiaQiang Pan. Hla-Dqb1 Reflects An Antigen-Presentation-Associated Immune Microenvironment In Bladder Cancer And Shows Response-Related Signals In An Atezolizumab-Treated Cohort. Eurasia Journal of Science and Technology. 2026, 8(5): 38-48. DOI: https://doi.org/10.61784/ejst3172.